ATR and rectal cancer: Chen et al. [28] reported that SCARNA2 was identified as the most enriched ATR-binding lncRNA and determined the effect of SCARNA2 on cellular sensitivity to DNA-damaging reagents and investigated the effects of SCARNA2 on radiotherapy in rectal-cancer-patient-derived organoids and xenograft preclinical models.